The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F14%3A%230004081" target="_blank" >RIV/00023728:_____/14:#0004081 - isvavai.cz</a>
Result on the web
<a href="http://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=18&SID=R1XyoWMGyYgLfotc7So&page=1&doc=1" target="_blank" >http://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=18&SID=R1XyoWMGyYgLfotc7So&page=1&doc=1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jash.2014.08.013" target="_blank" >10.1016/j.jash.2014.08.013</a>

Result language
angličtina
Original language name
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
Original language description
The OSKIRA-ambulatory blood pressure (BP) monitoring trial assessed the effect of fostamatinib on 24-hour ambulatory systolic BP (SBP) in patients with active rheumatoid arthritis. BP was measured at baseline and after 28 days of therapy. Fostamatinib increased 24-hour mean SBP by 2.9 mmHg (P = 0.023) and diastolic BP by 3.5 mmHg (P < 0.001) versus placebo. BP elevations resolved with fostamatinib discontinuation
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)